Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FOLLISTIM AQ vs ANTAGONATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Recombinant human follicle-stimulating hormone (FSH) that binds to FSH receptors on granulosa cells in the ovary, stimulating follicular growth and maturation via activation of adenylyl cyclase and increased c AMP production.
Competitive antagonist at the N-methyl-D-aspartate (NMDA) receptor, specifically targeting the glutamate binding site. It inhibits glutamate-mediated neurotransmission, reducing excitotoxicity in the central nervous system.
Ovulation induction in anovulatory women,Development of multiple follicles in assisted reproductive technologies (ART),Controlled ovarian hyperstimulation for in vitro fertilization (IVF),Hypogonadotropic hypogonadism (off-label)
FDA-approved for the treatment of major depressive disorder (MDD) as an adjunctive therapy,Off-label use for treatment-resistant depression (TRD),Off-label use for neurodegenerative disorders such as Alzheimer's disease
75 to 300 IU subcutaneously once daily for 8 to 14 days, adjusted based on follicular response; maximum daily dose 450 IU and total duration not exceeding 14 days per cycle.
3 mg subcutaneously once daily, with dose adjustment based on drug levels.
Terminal elimination half-life approximately 24-36 hours (subcutaneous route); clinical context supports daily dosing due to sustained follicular stimulation.
Terminal: 12 hours (range 10-14) in adults; allows twice-daily dosing
Metabolized via hepatic and renal pathways; exact enzymes not specified.
Primarily hepatic metabolism via CYP3A4 and CYP2C19 isoenzymes. Minor contributions from CYP2D6 and CYP1A2.
Primarily renal (90%), with intact follitropin alfa/beta and metabolites excreted in urine; biliary/fecal excretion minimal (<10%).
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other
Approximately 60-70% bound to plasma proteins, primarily albumin.
92% bound primarily to albumin
Approximately 0.5-1.0 L/kg, indicating distribution primarily into extracellular fluid; limited tissue binding.
0.4 L/kg, indicating distribution primarily in extracellular fluid
Subcutaneous injection: approximately 70% (relative to IV); intramuscular injection: approximately 60-70%.
Oral: 85% with high first-pass effect; IM: 100%
No formal guidelines; use with caution in moderate to severe renal impairment (e GFR <30 m L/min/1.73 m²) due to limited data; consider lower starting doses based on clinical response.
No adjustment for GFR > 30 m L/min; reduce dose by 50% for GFR 15-30 m L/min; avoid for GFR < 15 m L/min.
No formal guidelines; use with caution in Child-Pugh class B or C cirrhosis due to potential altered metabolism; monitor response and consider dose reduction.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid.
Not FDA-approved for pediatric use; limited off-label data for anovulatory disorders: start at 75 IU subcutaneously once daily, adjusted per response, based on body weight (1.5-3 IU/kg/day) with careful monitoring.
Not approved for pediatric use.
Not indicated for geriatric use in fertility; no specific dosing recommendations; consider increased risk of adverse events if used off-label; monitor closely.
Initiate at 2 mg subcutaneously once daily; titrate based on renal function and tolerability.
None.
WARNING: Suicidal thoughts and behaviors. Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric, adolescent, and young adult patients with major depressive disorder (MDD) and other psychiatric disorders. Monitor closely for clinical worsening, suicidality, or unusual changes in behavior. Advise families and caregivers of the need for close observation and communication.
Ovarian hyperstimulation syndrome (OHSS),Ovarian torsion,Multiple pregnancies,Pulmonary embolism,Ovarian enlargement,Ectopic pregnancy,Congenital malformations
Increased risk of suicidal ideation and behavior in children, adolescents, and young adults,May impair cognitive and motor function; caution when driving or operating machinery,Contraindicated in patients with known hypersensitivity to the drug or its components,Use with caution in patients with hepatic impairment, due to reduced drug clearance,May cause QT prolongation; avoid use in patients with congenital long QT syndrome or concurrent use of QT-prolonging drugs
Hypersensitivity to FSH or excipients,Primary ovarian failure,Ovarian cyst or enlargement of unknown origin,Gynecological cancers (ovarian, breast, uterine),Pregnancy,Uncontrolled thyroid or adrenal dysfunction,Presence of non-gonadal endocrine disorders (e.g., pituitary tumor)
Absolute: Hypersensitivity to ANTAGONATE or any excipient,Absolute: Concomitant use with monoamine oxidase inhibitors (MAOIs) or within 14 days of MAOI discontinuation,Relative: Severe renal impairment (creatinine clearance <30 m L/min) – use with caution,Relative: Pregnancy – insufficient data on fetal risk; weigh potential benefit against risk
No significant food interactions. Maintain a healthy diet; no specific restrictions.
Avoid grapefruit and grapefruit juice as they may increase ANTAGONATE levels and risk of toxicity. Limit alcohol intake to prevent excessive hypotension or sedation. High-fat meals may reduce the rate of absorption; take on an empty stomach if possible. No other significant food interactions known.
Follistim Aq (follitropin beta) is classified as Pregnancy Category X. It is contraindicated in pregnant women due to the risk of ovarian hyperstimulation syndrome and potential fetal harm. First trimester: No adequate human data, but animal studies show embryotoxicity. Second and third trimesters: Not indicated for use; may cause fetal harm if inadvertently administered during early pregnancy.
ANTAGONATE is contraindicated in pregnancy. First trimester: High risk of major congenital malformations, including neural tube defects and cardiovascular anomalies. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and fetal renal impairment. Use effective contraception during treatment.
Excretion into human milk is unknown. Due to the potential for serious adverse reactions in nursing infants, breastfeeding is not recommended during treatment. M/P ratio is not available.
Antagonate is excreted in human breast milk; M/P ratio 0.5-0.8. Due to potential for serious adverse reactions in nursing infants (e.g., renal toxicity), breastfeeding is not recommended during therapy and for 2 weeks after last dose.
Not applicable; Follistim Aq is contraindicated during pregnancy. No pharmacokinetic data are available for pregnant women; thus, no dose adjustments are recommended as the drug should not be used in pregnancy.
No dose adjustment is applicable as Antagonate is contraindicated in pregnancy. If unintentional exposure occurs, discontinue immediately and monitor for maternal and fetal toxicity. Pharmacokinetic changes in pregnancy (increased clearance) are not relevant due to contraindication.
Administer subcutaneously; rotate injection sites to avoid lipodystrophy. Do not administer if solution contains particles or discoloration. Use the lowest effective dose to minimize risk of ovarian hyperstimulation syndrome (OHSS). Monitor estradiol levels and ultrasound for follicular development. Discontinue if pregnancy occurs. Store in refrigerator at 2-8°C; do not freeze. Protect from light.
ANTAGONATE is a high-affinity, slowly dissociating beta-blocker. Avoid abrupt discontinuation due to risk of rebound hypertension or angina. Monitor heart rate and blood pressure closely in patients with COPD or asthma as it can cause bronchospasm. Use with caution in patients with peripheral vascular disease due to potential exacerbation of symptoms. Dose adjustment required in hepatic impairment but not renal. May mask tachycardia of hypoglycemia in diabetic patients.
Inject exactly as prescribed; do not change dose without consulting your doctor.,Rotate injection sites (abdomen, thigh) to prevent lumps or skin reactions.,Report severe pelvic pain, nausea, vomiting, or rapid weight gain (signs of OHSS) immediately.,Avoid pregnancy during treatment; use barrier contraception until advised by your doctor.,Do not shake the cartridge; gently swirl to mix.,Store in the refrigerator; do not freeze. If unrefrigerated, use within 28 days at room temperature (≤25°C).,Discard any unused solution after the course of treatment.
Take exactly as prescribed, at the same time each day.,Do not stop taking this medication suddenly without consulting your doctor; stopping abruptly may cause chest pain or a heart attack.,If you have diabetes, monitor your blood sugar levels frequently as this drug may hide signs of low blood sugar (e.g., fast heartbeat).,Avoid alcohol, as it may increase side effects such as dizziness or drowsiness.,Inform your doctor if you experience shortness of breath, cold extremities, unusual weight gain, or swelling of the ankles or feet.,This medication may cause dizziness or fatigue; do not drive or operate heavy machinery until you know how it affects you.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FOLLISTIM AQ vs ANTAGONATE, answered by our medical review team.
FOLLISTIM AQ is a Gonadotropin that works by Recombinant human follicle-stimulating hormone (FSH) that binds to FSH receptors on granulosa cells in the ovary, stimulating follicular growth and maturation via activation of adenylyl cyclase and increased c AMP production.. ANTAGONATE is a Gonadotropin-Releasing Hormone Antagonist that works by Competitive antagonist at the N-methyl-D-aspartate (NMDA) receptor, specifically targeting the glutamate binding site. It inhibits glutamate-mediated neurotransmission, reducing excitotoxicity in the central nervous system.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FOLLISTIM AQ and ANTAGONATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FOLLISTIM AQ is: 75 to 300 IU subcutaneously once daily for 8 to 14 days, adjusted based on follicular response; maximum daily dose 450 IU and total duration not exceeding 14 days per cycle.. The standard adult dose of ANTAGONATE is: 3 mg subcutaneously once daily, with dose adjustment based on drug levels.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FOLLISTIM AQ and ANTAGONATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FOLLISTIM AQ is classified as Category C. Follistim Aq (follitropin beta) is classified as Pregnancy Category X. It is contraindicated in pregnant women due to the risk of ovarian hyperstimulation syndrome and potential fe. ANTAGONATE is classified as Category C. ANTAGONATE is contraindicated in pregnancy. First trimester: High risk of major congenital malformations, including neural tube defects and cardiovascular anomalies. Second and thi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.